Coronavirus Vaccine
-
Coronavirus vaccine will hopefully be available in open market by year-end, says AIIMS director
Scroll Staff
-
Coronavirus: India records 11,610 cases, 100 deaths in a day; recovery rate at 97.3%
Scroll Staff
-
Coronavirus: SC to hear plea seeking priority vaccination for lawyers, judges
Scroll Staff
-
Coronavirus: India’s daily cases fall below 10,000 fourth time this month with 9,121 new infections
Scroll Staff
-
Coronavirus: WHO grants emergency approval to AstraZeneca vaccine for distribution through COVAX
Scroll Staff
-
Coronavirus: Maharashtra records 4,092 cases in a day, Kerala’s tally crosses 10 lakh
Scroll Staff
-
Coronavirus: People over 50 years to get vaccine from March, says AIIMS chief
Scroll Staff
-
Covid-19: Covaxin ‘safe and immunogenic’ says health minister after Chhattisgarh flags ‘inhibition’
Scroll Staff
-
Coronavirus: India registers 12,293 new infections, active cases rise by 1,051
Scroll Staff
-
Coronavirus: India records 9,110 new infections, active cases now 1.43 lakh
Scroll Staff
-
Coronavirus: India registers 11,831 cases, toll goes up by 84 to 1.54 lakh
Scroll Staff
-
The big news: Internet curbs at Delhi borders after farmers’ ‘chakka jam’, and 9 other top stories
Scroll Staff
-
Covid-19: Second dose of vaccination to begin on February 13 for those who took shots on first day
Scroll Staff
-
Coronavirus: AstraZeneca vaccine effective against UK variant, says Oxford University
Scroll Staff
-
Coronavirus: Pfizer withdraws application for emergency-use approval of its vaccine in India
Scroll Staff
-
21.5% of India’s population has past exposure to coronavirus, shows ICMR’s third sero survey
Scroll Staff
-
Coronavirus: India’s tally rises to 1.07 crore, active cases below 2 lakh for over two weeks
Scroll Staff
-
Coronavirus: Oxford vaccine gives good immune response in elderly, says trial chief amid controversy
Scroll Staff
-
Coronavirus: Over 41 lakh health workers vaccinated so far, says health ministry
Scroll Staff
-
Coronavirus: Russia’s Sputnik V vaccine shows 91.6% efficacy in phase 3 trials
Scroll Staff